XML 22 R12.htm IDEA: XBRL DOCUMENT
v3.23.2

Long-Term Investments | 6 Months Ended
--- | ---
Jun. 30, 2023
Long-Term Investments [Abstract] |
LONG-TERM INVESTMENTS | 5. LONG-TERM INVESTMENTS
(1) | The ownership percentages of each investee are listed as follows:
|  | Ownership percentage |  |  |
|  | June 30, |  |  | December 31, |  |  | Accounting
Name of related party |  | 2023 |  |  | 2022 |  |  | treatments
Braingenesis Biotechnology Co., Ltd. |  |  | 0.22 | % |  |  | 0.22 | % |  | Cost Method
Genepharm Biotech Corporation |  |  | 0.92 | % |  |  | 0.92 | % |  | Cost Method
BioHopeKing Corporation |  |  | 8.03 | % |  |  | 8.03 | % |  | Cost Method
BioFirst Corporation |  |  | 21.77 | % |  |  | 21.77 | % |  | Equity Method
Rgene Corporation |  |  | 28.85 | % |  |  | 28.85 | % |  | Equity Method
(2) | The extent the investee relies on the company for its business are summarized as follows:
Name of related party |  | The extent the investee relies on the Company for its business
Braingenesis Biotechnology Co., Ltd. |  | No specific business relationship
Genepharm Biotech Corporation |  | No specific business relationship
BioHopeKing Corporation |  | Collaborating with the Company to develop and commercialize drugs
BioFirst Corporation |  | Loaned from investee and provides research and development support service
Rgene Corporation |  | Collaborating with the Company to develop and commercialize drugs
(3) | Long-term investment mainly consists of the following:
|  | June 30, 2023 |  |  | December 31, 2022 |
|  | (Unaudited) |  |  |  |
Non-marketable Cost Method Investments, net |  |  |  |  |  |
Braingenesis Biotechnology Co., Ltd. |  | $ | 7,081 |  |  | $ | 7,169 |
Genepharm Biotech Corporation |  |  | 21,617 |  |  |  | 21,887 |
BioHopeKing Corporation |  |  | 803,008 |  |  |  | 813,014 |
Sub total |  |  | 831,706 |  |  |  | 842,070 |
Equity Method Investments, net |  |  |  |  |  |  |  |
BioFirst Corporation |  |  | - |  |  |  | - |
Rgene Corporation |  |  | - |  |  |  | - |
Total |  | $ | 831,706 |  |  | $ | 842,070 |
(a) | BioFirst Corporation (the “BioFirst”):
The Company holds an equity interest in BioFirst Corporation, accounting for its equity interest using the equity method to accounts for its equity investment as prescribed in ASC 323, Investments—Equity Method and Joint Ventures (“ASC 323”). Equity method adjustments include the Company’s proportionate share of investee’s income or loss and other adjustments required by the equity method. As of June 30, 2023 and December 31, 2022, the Company owns 21.77% and 21.77% common stock shares of BioFirst, respectively. The Company made prepayment for equity investment in BioFirst to purchase additional 317,000 shares to be issued by BioFirst in the aggregate amount of $610,542 and $618,150, recorded as prepayment for long-term investments as of June 30, 2023 and December 31, 2022, respectively. Summarized financial information for the Company’s equity method investee, BioFirst, is as follows: Balance Sheet
|  | June 30, 2023 |  |  | December 31, 2022 |
|  | (Unaudited) |  |  |  |
Current Assets |  | $ | 1,727,649 |  |  | $ | 1,543,152 |
Non-current Assets |  |  | 644,654 |  |  |  | 739,472 |
Current Liabilities |  |  | 3,375,670 |  |  |  | 2,663,051 |
Non-current Liabilities |  |  | 367,002 |  |  |  | 103,447 |
Stockholders’ Equity (Deficit) |  |  | (1,370,369 | ) |  |  | (483,874 | )
Statement of Operations
|  | Six months Ended June 30, |
|  | 2023 |  |  | 2022 |
|  | (Unaudited) |
Net sales |  | $ | - |  |  | $ | 15,398 |
Gross profit |  |  | - |  |  |  | 3,375 |
Net loss |  |  | (788,788 | ) |  |  | (872,254 | )
Share of losses from investments accounted for using the equity method |  |  | - |  |  |  |  |
(b) | Rgene Corporation (the “Rgene”)
Both Rgene and the Company are under common control by Dr. Tsung-Shann Jiang, the CEO and Chairman of the BioLite Inc. Since Dr. Tsung-Shann Jiang is able to exercise significant influence, but not control, over the Rgene, the Company determined to use the equity method to account for its equity investment as prescribed in ASC 323, Investments—Equity Method and Joint Ventures (“ASC 323”). Equity method adjustments include the Company’s proportionate share of investee’s income or loss and other adjustments required by the equity method. As of June 30, 2023 and December 31, 2022, the Company owns 28.85% and 28.85% Common Stock shares of Rgene, respectively. On March 31, 2023, Dr. Tsung-Shann Jiang has been elected to become the Chairman of Rgene. Summarized financial information for the Company’s equity method investee, Rgene, is as follows: Balance Sheets
|  | June 30, 2023 |  |  | December 31, 2022 |
|  | (Unaudited) |  |  |  |
Current Assets |  | $ | 56,752 |  |  | $ | 68,302 |
Noncurrent Assets |  |  | 250,077 |  |  |  | 303,893 |
Current Liabilities |  |  | 2,416,522 |  |  |  | 2,478,868 |
Noncurrent Liabilities |  |  | 1,268 |  |  |  | 2,441 |
Shareholders’ Deficit |  |  | (2,100,961 | ) |  |  | (2,109,114 | )
Statement of Operations
|  | Six months Ended June 30, |
|  | 2023 |  |  | 2022 |
|  | (Unaudited) |
Net sales |  | $ | - |  |  | $ | - |
Gross Profit |  |  | - |  |  |  | - |
Net loss |  |  | (155,873 | ) |  |  | (295,517 | )
Share of loss from investments accounted for using the equity method |  |  | - |  |  |  | - |
(4) | Disposition of long-term investment
During the six months ended June 30, 2023 and 2022, there is no disposition of long-term investment.
(5) | Losses on Equity Investments
The components of losses on equity investments for each period were as follows:
|  | Six months Ended June 30, |
|  | 2023 |  |  | 2022 |
|  | (Unaudited) |
Share of equity method investee losses |  | $ | - |  |  | $ | - |

X
- Definition The entire disclosure for long term investment. + References No definition available. + Details
Name: | abvc_LongTermInvestmentTextBlock
Namespace Prefix: | abvc_
Data Type: | dtr:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_LongTermInvestmentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration